CDKN2A and familial pancreatic carcinoma: Moreover, genes, frequently overexpressed in pancreatic cancer, such as KRAS, CDKN2A, TP53, and SMAD4,388 could serve as potential targets for PROTAC-based therapies in the treatment of pancreatic cancer.